Rapid bench-to-human development of safe and effective aerosol vaccine strategies against Covid-19 [Added supplement: COVID-19 Variant Supplement]

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:0 publications

Grant number: 172709, 175496

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2022
  • Known Financial Commitments (USD)

    $1,480,238.75
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principle Investigator

    Pending
  • Research Location

    Canada, Americas
  • Lead Research Institution

    McMaster University
  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Clinical trial (unspecified trial phase)

  • Special Interest Tags

    Gender

  • Study Subject

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The pandemic of Covid-19 caused by respiratory SARS-CoV-2 infection has brought the world to a standstill. The physical-distancing strategy currently implemented in the pandemic aims to prevent the majority of Canadians from being infected by SARS-CoV-2. While this is an essential short-term strategy to save lives, it will paradoxically leave the majority of our citizens without protective immunity against Covid-19. Thus, the majority of Canadians will be susceptible to the next waves of Covid-19. The only effective way to prevent new outbreaks from getting out of control is to establish herd immunity via implementing a safe and effective vaccination program prior to the next waves of Covid-19. High-risk Canadians including healthcare workers, seniors and indigenous people are especially in need of such vaccine-induced protective immunity. A global effort has been initiated to identify effective Covid-19 vaccines, testing a variety of vaccine platforms and strategies. Unfortunately, only a few of them are being developed and tested in Canada and almost none of them are designed to target respiratory mucosal immunity. To fill the gap, via the effort from a multi-disciplinary McMaster Team we have been rapidly developing innovative recombinant viral-vectored Covid-19 vaccine strategies to target the desired respiratory mucosal immunity. Our Team has internationally recognized reputation in bench-to-human translational vaccine research. Particularly relevant to the proposal is our strong expertise in advanced viral vector bioengineering, vaccine efficacy testing in small animal models at CL3 facility, clinical-grade vaccine production at GMP manufacturing facility, optimized inhaled aerosol vaccine delivery method, and clinical vaccine trials. We are confident that our project will make available to Canadians a superb, needle/pain-free vaccine strategy capable of potent respiratory mucosal protection against Covid-19.